SUMMARY
Hugo E. Vargas, M.D., focuses his research on the prevention and improvement of liver damage with the aim of avoiding or curtailing the impact of cirrhosis. He conducts clinical trials that introduce techniques, devices and pharmacological approaches to improve the lives of people with liver disease. Dr. Vargas has expertise in the development of current therapies for chronic hepatitis C.
He researches therapeutic approaches for the management of complications of portal hypertension such as ascites, variceal bleeding and hepatic encephalopathy. Dr. Vargas works extensively in the management of liver complications as they pertain to individuals who receive liver transplantation or have conditions that cause cirrhosis. He also focuses on developing strategies for people with alpha-1 antitrypsin deficiency (A1ATD)-related liver disease. A1ATD is a genetic disease that damages the liver. His research on A1ATD-related liver disease will include clinical trials and participation in national data collection with experts in pulmonary medicine.
Focus areas
- Portal hypertension. Dr. Vargas researches the management and treatment of hepatorenal syndrome, conducts vasoactive therapy clinical trials, and pursues Alfapump clinical trials and management strategies for refractory ascites.
- A1ATD. Dr. Vargas supports the national Alpha-1 Foundation Clinical Resource Center. The center provides care and clinical trial and scientific registry entry for people with A1ATD-related liver disease.
- Alcohol-related liver disease. Dr. Vargas participates in industry- and National Institutes of Health (NIH)-funded efforts to treat those with alcohol use disorder and alcohol-related hepatitis.
- Liver transplantation. Dr. Vargas is part of NIH-funded clinical trials in organ transplantation efforts, currently looking at immunosuppression reduction strategies after liver transplantation. Immunosuppression reduction may improve the survival and quality of life of liver transplant recipients.
Significance to patient care
Dr. Vargas' research serves as an important translational pivot point where new therapeutic ideas are investigated. These new therapies may improve quality of life and change clinical outcomes of people with diseases that affect the liver — and eventually heal these diseases. His focus continues to be delivering innovation between individuals and the healthcare system. This is especially important when a person presents with advanced liver disease and may need liver transplantation.
Professional highlights
- Mayo Clinic in Arizona:
- Advisor, residency program research, Department of Medicine, 2024-present.
- Director, research, Mayo Clinic Alix School of Medicine, 2016-present.
- Director, clinical trials office, 2013-2023.
- Investigator of the Year Award, 2016.
- Outstanding Program Director of the Year, Mayo School of Continuous Professional Development, Mayo Clinic College of Medicine, Department of Education Administration, 2010.
- Educator of the Year Award for Research, 2003.
- Fellow, American Society for Gastrointestinal Endoscopy, 2019-present.
- American Association for the Study of Liver Diseases:
- Chair, Hepatitis C Virus Guidance Panel, 2014-present.
- Fellow, 2014-present.
- Fellow, American Gastroenterological Association, 2006-present.
- Fellow, American College of Gastroenterology, 2005-present.
- Fellow, American College of Physicians, 2005-present.
- Member, Infectious Disease Society of America, 2015-2018.